CAMO 2021 VIRTUAL MEETING

FINAL PROGRAM

The National CAMO Residents Research Day | Thursday, April 1, 2021
The CAMO Virtual Annual Scientific Meeting & AGM | Thursday, April 22, 2021
CAMO 2021 VIRTUAL MEETING

Overall Objectives
1. Describe how value assessment is used in cancer drug funding in Canada.
2. Develop an approach to obtaining funding of new cancer treatments for Canadian patients.
3. Compare and contrast the current Canadian experience in private and publicly funded cancer care.
4. Establish and promote a network of medical oncology colleagues from both community and academic settings.

Scientific Planning Committee (SPC)

Co-Chairs
Dr. Erin Powell
Dr. Jonathan Loree

Committee Members
Dr. Desiree Hao
Dr. Sharlene Gill
Dr. Stephen Welch
Dr. Bruce Colwell

CPD Representative
Dr. Ghazaleh Kazemi

Use #CAMO21 when you tweet to participate in virtual conversations & share what you’re learning with colleagues.
2021
The National CAMO Residents Research Day

April 1, 2021 (all times listed are in EST)

OPEN TO ALL

11h00-11h05  Introduction to the National CAMO Residents Research Day
Dr. Erin Powell & Dr. Jonathan Loree

11h05-13h05  Oral Presentations (12 presentations)
Objectives (7-minute presentation, followed by 3-minute Q&A)
At the end of the session, participants will be able to:
1. Describe recent research findings in the field of Medical Oncology.
2. Describe interesting cases in the field of Medical Oncology.

- 11h05-11h15: Jennifer Leigh: BARRIERS TO ACCESS OF CONTEMPORARY TREATMENT FOR LETHAL PROSTATE CANCER: AN ONTARIO POPULATION-BASED STUDY
- 11h15-11h25: Michela Febbraro: A REVIEW OF OBSP SCREENING TRENDS ACROSS THE PROVINCE – A RETROSPECTIVE POPULATION-BASED STUDY USING ADMINISTRATIVE DATA
- 11h25-11h35: Erica Tsang: BEYOND BRCA? CLINICAL UTILITY OF HOMOLOGOUS RECOMBINATION DEFICIENCY IN GASTROINTESTINAL CANCERS
- 11h35-11h45: Carla Pires Amaro: DOSING, EFFICACY AND SAFETY OF LENVATINIB IN THE REAL-WORLD TREATMENT OF HEPATOCELLULAR CARCINOMA: RESULTS FROM A CANADIAN MULTICENTER DATABASE (HCC CHORD)
- 11h45-11h55: Suganija Lakkunarajah: THE INFLUENCE OF ADJUVANT CHEMOTHERAPY DOSE INTENSITY ON OVERALL SURVIVAL IN RESECTED COLON CANCER: A MULTICENTRE RETROSPECTIVE ANALYSIS
- 11h55-12h05: Megan Tesch: IMPACT OF TAILORX DATA ON CHEMOTHERAPY PRESCRIBING IN BRITISH COLUMBIA
- 12h05-12h15: Alexander Watson: OPTIMIZING CABAZITAXEL (CBZ) VS NOVEL ANTI-ANDROGENS (NAA) ABIRATERONE (ABI) OR ENZALUTAMIDE (ENZ) POST-DOCETAXEL (DTX) IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
- 12h15-12h25: Xin Ye Wang: REAL WORLD OUTCOMES OF METASTATIC BREAST CANCER PATIENTS WITH BRAIN METASTASES TREATED WITH RADIOTHERAPY IN ONTARIO: A POPULATION-BASED STUDY
- 12h25-12h35: Scott Strum: EXAMINATION OF FEBRILE NEUTROPENIA AND THE UTILIZATION OF G-CSF ON HEALTHCARE SYSTEMS
- 12h35-12h45: Selina Wong: CURRENT ATTITUDES TOWARD UNFUNDED CANCER THERAPIES AMONG CANADIAN MEDICAL ONCOLOGISTS
- 12h45-12h55: Kim Koczka: PROGNOSTIC PATHOLOGICAL AND CLINICAL FACTORS ASSOCIATED WITH OVERALL SURVIVAL IN METASTATIC MELANOMA UNDERGOING ANTI PD-1 TREATMENT
- 12h55-13h05: Nicholas Bosma: EFFICACY OF PERIOPERATIVE CHEMOTHERAPY IN RESECTED COLORECTAL LIVER METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

13h05-13h10  Break
The National CAMO Residents Research Day

April 1, 2021 (all times listed are in EST)

OPEN TO ALL

13h10-13h35 Rapid Fire Presentations (8 presentations)
Objectives (3-minute presentation, followed by discussion period)
At the end of the session, participants will be able to:
1. Describe recent research findings in the field of Medical Oncology.
2. Describe interesting cases in the field of Medical Oncology.

- 13h10-13h13: Jasna Deluce: EFFICACY AND TOXICITY OF COMBINED INHIBITION OF EGFR AND VEGFR IN ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS HARBORING ACTIVATING EGFR MUTATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS
- 13h13-13h16: Rania Chehade: PD-L1 EXPRESSION IN BREAST CANCER BRAIN METASTASES
- 13h16-13h19: Sally Lau: OUTCOMES OF ELDERLY PATIENTS WITH UNRESECTABLE STAGE 3 NSCLC TREATED WITH DEFINITIVE CHEMORADIATION WITH OR WITHOUT DURVALUMAB
- 13h19-13h21: Kieran Sharma: IMPACT OF SMOKING ON RESPONSE TO IMMUNOTHERAPY IN KRAS MUTANT NON-SMALL CELL LUNG CANCER
- 13h21-13h24: Charlie Yang: OGIVRI VERSUS HERCEPTIN – “REAL WORLD” PCR RATES IN PATIENTS WITH HER2+ BREAST CANCER TREATED WITH NEOADJUVANT CHEMOTHERAPY PLUS TRASTUZUMAB FROM ALBERTA, CANADA
- 13h24-13h27: Margaret Sheridan: THE EFFECT OF THE COVID-19 PANDEMIC ON THE EVOLUTION OF CANCER CARE IN NOVA SCOTIA
- 13h27-13h30: Rebekah Rittberg: POPULATION-BASED IMPACTS OF NEW THERAPIES ON OUTCOMES FOR STAGE IV NON-SMALL CELL LUNG CANCER
- 13h30-13h33: Ryan Holstead: INCREASED SURVIVAL IN PATIENTS WITH MELANOMA WHO DEVELOP IMMUNE RELATED ADVERSE EVENTS: A REAL-WORLD RETROSPECTIVE STUDY

13h35-13h45 Discussion Period

13h45-13h55 Break
2021
The National CAMO Residents Research Day

April 1, 2021 (all times listed are in EST)

CLOSED SESSION FOR RESIDENTS-FELLOWS-MEDICAL STUDENTS

13h55-14h00 Breakout Session Introduction

14h00-14h25 Breakout Sessions 1 (concurrent) 25-minute interactive discussions
At the end of the session, participants will be able to:

Choose one

1a. Building a Career in Medical Education as a Medical Oncologist.
   Moderated by Dr. Neil Reaume
   Objective: Describe opportunities to build a career in medical education.
1b. Jump In: Getting Involved in Clinical Trials as an Early Career Medical Oncologist.
   Moderated by Dr. Daniel Renouf
   Objective: Discuss opportunities to develop a career in clinical trials as early career investigator.
1c. Big Isn’t Always Better: Careers in Community Oncology.
   Moderated by Dr. Julie Lebert
   Objective: Gain further insight into the advantages and challenges of practicing community oncology.
   Moderated by Dr. Don Morris
   Objective: Describe the ying and yang of career choices surrounding research/education/administration in the setting of clinical service.

14h25-14h30 Break

14h30-14h55 Breakout Sessions 2 (concurrent) 25-minute interactive discussions
At the end of the session, participants will be able to:

Choose one

2a. Building a Career in Medical Education as a Medical Oncologist.
   Moderated by Dr. Neil Reaume
   Objective: Describe opportunities to build a career in medical education.
2b. Jump In: Getting Involved in Clinical Trials as an Early Career Medical Oncologist.
   Moderated by Dr. Daniel Renouf
   Objective: Discuss opportunities to develop a career in clinical trials as early career investigator.
2c. Big Isn’t Always Better: Careers in Community Oncology.
   Moderated by Dr. Julie Lebert
   Objective: Gain further insight into the advantages and challenges of practicing community oncology.
   Moderated by Dr. Don Morris
   Objective: Describe the ying and yang of career choices surrounding research/education/administration in the setting of clinical service.

14h55-15h00 Closing Remarks
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10h30-11h30</td>
<td>Annual General Meeting</td>
<td>(members ONLY/membres SEULEMENT)</td>
</tr>
<tr>
<td>11h30-11h45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11h45-11h50</td>
<td>Welcome remarks from CAMO President – Dr. Desiree Hao</td>
<td></td>
</tr>
</tbody>
</table>
| 11h50-12h50| Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults | * This session is co-developed with Bayer Inc.  
This symposium was co-developed with the Canadian Association of Medical Oncologists and Bayer Inc. and was planned to achieve scientific integrity, objectivity and balance  
Moderator: Dr. Stephanie Snow  
Speakers: Dr. Sharlene Gill & Dr. Gwyn Bebb  
Objectives (45-minute presentation + 15-minute Q&A)  
At the end of the session, participants will be able to:  
1. Review recently published Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults  
2. Discuss histology-specific algorithms for the testing and treatment of TRK fusion cancer  
3. Discuss delivery of precision oncology in the context of TRK fusion cancer with practical approaches in a rapidly changing testing environment |
| 12h50-13h00| Break                                                                  |                                                                         |
| 13h00-13h05| Sponsor Recognition – Dr. Desiree Hao                                  |                                                                         |
| 13h05-13h15| 2021 Fellowship Recipient & Best Resident Abstracts                   | Dr. Bindi Dheshy-Third – Chair, Fellowship Committee  
Dr. Erin Powell & Dr. Jonathan Loree – Co-chairs, ASM Committee |
| 13h15-15h15| CAMO SYMPOSIUM: I WANT A NEW DRUG... NAVIGATING NEWLY APPROVED AND UNFUNDED TREATMENT OPTIONS FOR CANADIAN ONCOLOGY PATIENTS |                                                                         |
| 13h15-14h00| Debate: Is A Two-Tier Healthcare System Already A Reality in Canada?    | Speakers: Dr. Sharlene Gill & Dr. Scott Berry  
Objectives (30-minute debate followed by 15-minute rebuttal and Q&A)  
At the end of the session, participants will be able to:  
1. Discuss the current Canadian landscape for access to systemic cancer therapies.  
2. Debate whether a two-tier healthcare system is already a reality in Canada |
2021
The CAMO Virtual Annual Scientific Meeting & AGM

April 22, 2021 (all times are in EST)

14h00-15h15  Panel Discussion – An Approach to Oncology Drug Reimbursement Decisions and Navigating Unfunded Options
Panelists: Dr. Helen Anderson, Dr. Nicole MacDonald, Ms. Mary Lou Robertson, Mr. Robert Bick, Dr. Sandy Sehdev
60-minute panel discussion, followed by 15-minute Q&A
At the end of the session, participants will be able to:
1. Identify important considerations from regulatory, funding, patient, and healthcare systems when approaching approval and access to novel drugs.
2. Explore considerations required in order for provincial formularies or third-party insurance to provide coverage for oncology drugs.
3. Define and explore the implications of orphan drugs, biosimilars, and compassionate access programs for patient care.
4. Discuss approaches to access if no funding avenue for a novel therapeutic is identified and a patient may benefit from it.

15h15-15h30  Closing remarks – Dr. Erin Powell & Dr. Jonathan Loree
The Canadian Association of Medical Oncologists gratefully acknowledges the continued support of our scientific program by educational grants from:

**DIAMOND LEVEL**

![Bayer](image)

**GOLD LEVEL**

- AbbVie
- AstraZeneca
- Ipsen

**SILVER LEVEL**

- Apobiologix
- Astellas

**BRONZE LEVEL**

- Advanced Accelerator Applications
- Amgen
- Janssen Oncology
- Pfizer
- Merck
- Takeda

**BEST RESIDENT ABSTRACT**

- Current Oncology